the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More (NCT06622603) | Clinical Trial Compass
RecruitingPhase 4
the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
South Korea59 participantsStarted 2025-09-10
Plain-language summary
The goal of this clinical trial is to compare the changes in serum urate levels and symptom recurrence after reducing or suspending urate-lowering agents in well-controlled gout patients (the 'after dishes are clean' state in the Dirty Dish hypothesis)
Researchers will compare three randomized groups: the reducing group takes febuxostat 20 mg once daily for 12 months, the discontinuing group takes a placebo once daily for 6 months, followed by febuxostat 20 mg once daily for the next 6 months, and the maintaining group continues their pre-study urate-lowering agents for 12 months, serving as an observational reference group.
During the 12-month study period, participants will visit every 3 months for laboratory evaluations including serum urate levels, and for checking symptomatic status using questionnaires and diaries. Additionally, musculoskeletal ultrasonography and serum sample collection will be performed at baseline to study predictors for maintaining serum urate levels \<7.0 mg/dL after reducing or suspending urate-lowering therapy.
Who can participate
Age range19 Years – 79 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adult gout patients aged ≥19 but \<80 years.
✓. Gout patients treated with urate-lowering therapy (either allopurinol or febuxostat monotherapy, or a combination of two agents) for at least the past 5 years.
✓. Patients who have at least five serum urate level measurements over the past 5 years and meet one of the following criteria:
✓. Patients without palpable or visible tophi on physical examination (evaluated at pre-defined 18 joint sites and the ears).
✓. Patients without acute gouty attack or history of nephrolithiasis in the past 12 months
✓. Patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73m² or higher, based on the Cockcroft-Gault formula.
✓. Patients who voluntarily provide written informed consent to participate.
Exclusion criteria
✕. Subjects who continuously require prophylactic low-dose colchicine/NSAIDs.
✕
What they're measuring
1
The proportion of patients with serum urate levels <7.0 mg/dL
. Subjects already having taken low-dose urate-lowering agents. The low-dose urate-lowering agents are defined as allopurinol ≤200 mg/day or febuxostat ≤20 mg/day. But patients on a combination of low-dose allopurinol and febuxostat are eligible.
✕. Subjects taking medications that could affect serum uric acid levels and uric acid fractional excretion rates, such as benzbromarone, fenofibrate, loop diuretics, thiazide or thiazide-like diuretics, and losartan.
✕. Subjects classified as having high-risk alcohol use according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA):
✕. Subjects with a history of hypersensitivity to febuxostat or allopurinol
✕. Subjects with unstable cardiovascular conditions, who require adjustment of urgent their therapy
✕. Subjects taking mercaptopurine or azathioprine
✕. Subjects with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption